Shanghai United Imaging Healthcare Co. Ltd. A

United Imaging Healthcare announced that as of July 31, 2026, the company had repurchased 2.62 million shares, accounting for 0.32% of total share capital, with a repurchase amount of 283 million yuan, at a price range of 99.21 yuan to 111.5 yuan per share. In the first quarter of 2026, United Imaging Healthcare achieved revenue of 2.908 billion yuan and net profit attributable to the parent of 399 million yuan.

The pharmaceutical sector saw a broad-based rally, with the Penghua STAR Market Healthcare ETF climbing 4.12% to 1.12 yuan. The Shanghai STAR Market Biomedical Index it tracks surged 3.66%. Institutions note that this rebound is a value revaluation driven by a triple resonance of capital, policy, and fundamentals. The core driver is a shift of funds from the previously high-flying tech sector into innovative drugs, which have better prospects and are trading near bottom levels. On the policy front, the state continues to increase support for the entire innovative drug industry chain. On the fundamentals side, overseas business development deals keep materializing, with innovative drug BD deal values in the first half of 2026 hitting a new high despite the high base in the same period of 2025. Institutions believe that there is strong willingness for further capital allocation, and the pace of overseas commercialization is clear. Innovative drugs are the core investment theme for the pharmaceutical sector over the next three to five years, and this rebound is merely an initial warm-up. As of June 30, 2026, the top ten constituents of the Shanghai STAR Market Biomedical Index accounted for 51.84% of the total weight, including United Imaging Healthcare, Allist Pharmaceuticals, and BeiGene.

A research note from China Securities points out that the medical device sector has reached an inflection point. In the first quarter of 2026, the pharmaceutical industry's total revenue grew 2.16% year on year, while core net profit attributable to shareholders rose 2.69%, showing an improving trend. The STAR Biomedical Index tracked by the STAR Healthcare ETF ChinaAMC has a medical device weighting exceeding 34%, with the top ten holdings including device leaders such as United Imaging Healthcare, Yirui Technology, and Huitai Medical. China Securities believes that as the impact of policies like volume-based procurement gradually fades, the device sector is poised for a dual recovery in valuations and earnings, with key opportunities coming from earnings recovery, overseas expansion, surgical robots, and brain-computer interfaces. As of 10 July 2026, the latest circulating size of the STAR Healthcare ETF ChinaAMC reached 249 million yuan, a new high over the past year.

Telix Pharmaceuticals and United Imaging Healthcare have signed a memorandum of understanding to establish a strategic research collaboration in the United States. The partnership will combine United Imaging's advanced scanner platforms, software, and AI capabilities with Telix's molecular imaging products and clinical protocols, initially focusing on TLX101-Px, a PET imaging candidate under FDA review for recurrent or progressive glioma. The companies aim to explore workflow efficiencies, standardize imaging performance, and develop data-driven clinical decision support tools to improve treatment planning and patient management. Future efforts may expand to additional markets and other candidates in Telix's pipeline.